Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Not yet recruiting
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Recruiting
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
NCT07005180· Phase 2· Hillhurst Biopharmaceuticals, Inc.· Source
Contact: Tamsin Andres
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Recruiting
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
NCT07633470· Phase 4· Alpha Cognition, Inc· Source
Contact: Aaron Ellenbogen
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595· Phase 2· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Recruiting
Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease
NCT07428447· CND Life Sciences· Source
Contact: Denise Morgott
Recruiting
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675· Phase 1· Serina Therapeutics· Source
Contact: Heather Fasczewski
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784· Phase 2/3· Annovis Bio Inc.· Source
Contact: Savannah Carra
Recruiting
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
NCT07280156· Phase 2· Protalix· Source
Contact: Head of Clinical Development
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· Phase 3· Bristol-Myers Squibb· Source
Contact: Aaron Ellenbogen, Site 0073
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
GyroGlove Use in Essential Tremor Patients
NCT05958030· GyroGear Ltd· Source
Contact: Peter LeWitt
Recruiting
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931· Phase 2· Ipsen· Source
Contact: Ipsen Clinical Study Enquiries
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
NCT06944522· Phase 3· BlueRock Therapeutics· Source
Contact: Patient Engagement
Recruiting
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT07051629· Phase 1· Suninflam Inc· Source
Contact: Aaron Ellenbogen, DO
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248· Phase 2· ModernaTX, Inc.· Source
Contact: Moderna WeCare Team
Active, not recruiting
A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease
NCT06773962· Phase 2· TrueBinding, Inc.· Source
Recruiting
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
NCT06809400· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Recruiting
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668· Phase 4· Impax Laboratories, LLC· Source
Contact: Aaron Ellenbogen
Active, not recruiting
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014· Phase 3· Annovis Bio Inc.· Source
Recruiting
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830· Phase 2· Neuron23 Inc.· Source
Contact: Nancy Virdi
Active, not recruiting
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572· Vertex Pharmaceuticals Incorporated· Source
Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768· Phase 1· Eli Lilly and Company· Source
Contact: Aaron Ellenbogen (principal investigator)
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· Phase 3· Eli Lilly and Company· Source
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· GAP Innovations, PBC· Source
Contact: Jorge Isunza
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Active, not recruiting
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
Parkinson's Disease Progression Study
NCT06219629· Koneksa Health· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444· Phase 3· Ipsen· Source
Active, not recruiting
GDNF Gene Therapy for Multiple System Atrophy
NCT04680065· Phase 1· Brain Neurotherapy Bio, Inc.· Source
Active, not recruiting
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457· Phase 3· Ipsen· Source
Active, not recruiting
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
NCT05923866· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717· Phase 3· Theravance Biopharma· Source
Active, not recruiting
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
NCT04006210· Phase 3· NeuroDerm Ltd.· Source
Active, not recruiting
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
NCT03100149· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
NCT02726386· Phase 2· NeuroDerm Ltd.· Source